BAD

BAD is a BH3-only pro-apoptotic BCL-2 family member that couples survival-kinase signaling to the mitochondrial apoptotic machinery, with its activity gated by multisite serine phosphorylation (PMID:9381178, PMID:19641507, PMID:12431365). In its unphosphorylated state, BAD localizes to mitochondria and heterodimerizes with the anti-apoptotic proteins BCL-2 and BCL-XL to promote cell death, whereas phosphorylation sequesters it away from mitochondria via 14-3-3 binding and neutralizes its death-promoting function (PMID:19641507). Survival signaling enforces this inhibition through several kinases: Akt phosphorylates BAD downstream of IL-3/PI 3-kinase to block its pro-apoptotic activity (PMID:9381178), while PKA and RSK1 phosphorylate Ser-155 within the BH3 domain to directly disrupt BAD–BCL-XL binding, a mechanism distinct from the Ser-112/Ser-136 phosphorylation that drives 14-3-3 sequestration (PMID:10837486). Conversely, the TSC2 tumor suppressor activates BAD by reducing Ser-136 phosphorylation through downregulation of p70S6K, increasing BAD/BCL-2 and BAD/BCL-XL heterodimerization to promote apoptosis (PMID:16702951). The balance of BAD phosphorylation (human S75, S99, S118) sets the pro-apoptotic versus pro-survival output, and dephosphorylation by PP2C-class phosphatases opposes the survival state; elevated phospho-BAD confers a growth advantage in cancer cells (PMID:25653146). Beyond apoptosis, BAD participates in non-apoptotic functions including the regulation of mitochondrial glucose metabolism (PMID:19641507).

1. 1997 High

   Established that survival signaling directly inactivates the death machinery by identifying Akt as the kinase that phosphorylates BAD downstream of IL-3/PI 3-kinase, linking growth-factor signaling to apoptosis suppression.

   Evidence In vitro kinase reconstitution plus in vivo phosphorylation analysis with PI 3-kinase inhibitors in IL-3-stimulated cells

   PMID:9381178

   Open questions at the time

   • Did not resolve how phosphorylation translates to subcellular relocalization away from mitochondria
   • Other survival kinases acting on BAD not yet mapped
2. 2000 High

   Resolved that BAD inhibition occurs through two mechanistically distinct phosphorylation modes, showing that Ser-155 phosphorylation within the BH3 domain directly blocks BCL-XL binding, separate from the Ser-112/Ser-136 sites that drive 14-3-3 sequestration.

   Evidence In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, and cell death rescue assays with PKA and RSK1

   PMID:10837486

   Open questions at the time

   • Relative contribution of each site to physiological survival signaling not quantified
   • Structural basis of BH3-domain phosphorylation blocking heterodimerization not determined
3. 2002 Medium

   Placed BAD genetically as the connector between survival kinase signaling and the apoptotic machinery in vivo, validating its pathway position across model organisms.

   Evidence Genetic epistasis and in vivo studies in Drosophila and mammals

   PMID:12431365

   Open questions at the time

   • Commentary-level synthesis rather than a single primary mechanistic dataset
   • Did not define tissue-specific kinase inputs
4. 2006 Medium

   Identified an upstream activator of BAD by showing the TSC2 tumor suppressor reduces Ser-136 phosphorylation via p70S6K downregulation and increases BAD/BCL-2 and BAD/BCL-XL heterodimerization to drive apoptosis.

   Evidence BAD-/- cell experiments, reciprocal co-immunoprecipitation, phosphorylation analysis, and TSC2 overexpression/knockdown

   PMID:16702951

   Open questions at the time

   • Phosphatase mediating the Ser-136 dephosphorylation not identified
   • Single-lab study with limited cell-type breadth
5. 2015 Medium

   Linked the BAD phosphorylation state to cancer cell survival by showing phospho-BAD is elevated in cancer cells and that PP2C depletion further raises phospho-BAD and confers a growth advantage.

   Evidence siRNA depletion of PP2C, MTS proliferation assays, immunofluorescence for phospho-BAD, RT-qPCR

   PMID:25653146

   Open questions at the time

   • Direct phosphatase–substrate relationship between PP2C and BAD not biochemically reconstituted
   • Specific PP2C isoform and target residues not pinpointed
6. 2017 Low

   Consolidated the model that three serine phosphosites (S75, S99, S118) toggle BAD between pro-apoptotic and pro-survival functions, including non-apoptotic roles in glycolysis, autophagy, and cell cycle.

   Evidence Review synthesizing prior in vitro and in vivo phosphorylation studies

   PMID:29175460

   Open questions at the time

   • Review without new primary experiments
   • Molecular mechanisms underlying the non-apoptotic glycolytic and autophagy roles not detailed

• How BAD mechanistically coordinates mitochondrial glucose metabolism with the apoptotic decision, and which phosphatases physiologically reactivate BAD, remain unresolved.
• No reconstituted mechanism connecting BAD phosphorylation to metabolic enzyme activity
• Physiological phosphatase(s) reactivating BAD in vivo not definitively established